

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> ( Not for submission under 37 CFR 1.99)	Application Number		10629123	
	Filing Date		2003-07-28	
	First Named Inventor	Pickar et al.		
	Art Unit	1617		
	Examiner Name	Layla Soroush		
	Attorney Docket Number	26811-010 UTIL		

U.S.PATENTS						
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

#### U.S.PATENT APPLICATION PUBLICATIONS

Examiner Initial*	Cite No	Publication Number	Kind Code <sup>1</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

#### FOREIGN PATENT DOCUMENTS

Examiner Initial*	Cite No	Foreign Document Number <sup>3</sup>	Country Code <sup>2</sup> j	Kind Code <sup>4</sup>	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T <sup>5</sup>
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button

#### NON-PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>5</sup>

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
( Not for submission under 37 CFR 1.99)

Application Number	10629123
Filing Date	2003-07-28
First Named Inventor	Pickar et al.
Art Unit	1617
Examiner Name	Layla Soroush
Attorney Docket Number	26811-010 UTIL

1	KAPUR ET AL., Serotonin-Dopamine Interaction and its Relevance to Schizophrenia, Am J Psychiatry, April 1996, Vol. 153, pp. 466-476.	<input type="checkbox"/>
2	MELTZER ET AL., Classification of Typical and Atypical Antipsychotic Drugs on the Basis of Dopamine D-1, D-2 and Serotonin <sub>2</sub> pKi Values <sup>1</sup> , The Journal of Pharmacology and Experimental Therapeutics by the American Society for Pharmacology and Experimental Therapeutics, June 1989, Vol. 251, No. 1.	<input type="checkbox"/>
3	STOCKMEIER ET AL., Characterization of Typical and Atypical Antipsychotic Drugs Based on in Vivo Occupancy of Serotonin <sub>2</sub> and Dopamine <sub>2</sub> Receptors <sup>1</sup> , The Journal of Pharmacology and Experimental Therapeutics by the American Society for Pharmacology and Experimental Therapeutics, May 1993, Vol. 266, No. 3.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

**EXAMINER SIGNATURE**

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Kind Codes of USPTO Patent Documents at [www.USPTO.GOV](http://www.USPTO.GOV) or MPEP 901.04. <sup>2</sup> Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>3</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>4</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>5</sup> Applicant is to place a check mark here if English language translation is attached.